Intercept is a biopharmaceutical company that develops and commercializes novel therapeutics to treat non-viral liver diseases.Read more
Acorda is Intercept's #1 competitor. Acorda's headquarters is in Ardsley, New York, and was founded in 1995. Acorda competes in the Biotechnology industry. Acorda generates 47% of Intercept's revenue.
Akcea is one of Intercept's top rivals. Akcea was founded in Boston, Massachusetts} in 2015. Like Intercept, Akcea also works within the Pharmaceuticals sector. Compared to Intercept, Akcea generates $167.3M more revenue.
Intercept's revenue is the ranked 3rd among it's top 10 competitors. The top 10 competitors average 7B. Over the last four quarters, Intercept's revenue has grown by 5.7%. Specifically, in Q1 2021's revenue was $81.7M; in Q4 2020, it was $83.3M; in Q3 2020, it was $79.5M; in Q2 2020, Intercept's revenue was $77.2M.
No recent acquisitions found related to Intercept
No recent investments found related to Intercept